Option chain shows key data for Evogene's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Evogene.

Evogene (NASDAQ:EVGN) Stock, Option Chain

Evogene

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.

News

BASFY

EVGN

THRY

Evogene&#39;s stock surged on news of ICL&#39;s acquisition of Lavie Bio&#39;s operations, strengthening ICL&#39;s position in ag-biologicals.

Evogene Stock Soars After ICL Deal To Acquire Lavie Bio, MicroBoost AI

pepi-stojanovski-MJSFNZ8BAXw-unsplash

Cannabis

Earnings

Evogene Ltd. released its fourth-quarter and full-year 2023 financial results, showing a 237% revenue increase for the year. Despite a 12% revenue decrease in Q4, the Israeli cannabis company reported $5.6 million in total revenue for the year. CEO Ofer Haviv highlighted the company&#39;s successful collaborations with industry leaders like Corteva, ICL, and Syngenta, contributing to revenue growth. In Q4, gross profit decreased to $180,000, but net financing income rose to $287,000. Total operating expenses increased to $7.8 million, leading to a net loss of $7.3 million. For the full year, gross profit reached $3.9 million, and net financing income was approximately $521,000. Evogene also secured partnerships with Verb Biotics and Colors Farm, along with receiving a €1.2 million EU grant for its Ag-Seed Division&#39;s research and development efforts.

Israeli Company Reports Record 2023 Revenue, Wants To Transition Cannabis Operations To &#39;Third Party&#39;

rick-proctor-PGc9Vid8O24-unsplash

Earnings Beats

Evogene reports a strong Q3 with $3.8M revenue and significant gross profit growth, showcasing resilience and innovation in cannabis tech.

Israeli Cannabis Company Reports Strong Q3 Despite Geopolitical Challenges

Evogene Ltd

Press Releases

"The Future is Bright: Peraso Inc. (NASDAQ: PRSO) Expands Technology for Tactical Applications in High-Demand Industries – More Stocks Inside…"

Evogene Schedules Third Quarter 2024 Financial Results Release

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

Evogene Reports Third Quarter 2024 Financial Results

AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease

Evogene Schedules Fourth Quarter 2024 Financial Results Release

Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

Comments

Evogene

Evogene (EVGN) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell